MSCI Inc. vs AbbVie

About

MSCI Inc. is a New York City-based financial data, index, and analytics company — publicly traded on the New York Stock Exchange (NYSE: MSCI) as an S&P 500 Financials component — providing investment decision support tools including equity and fixed income indices (MSCI World Index, MSCI Emerging Markets Index, MSCI ACWI), portfolio analytics (BarraOne, RiskManager, Optimizer), ESG and climate data and ratings, and real assets data (private real estate, infrastructure, private equity indices) through approximately 5,500 employees in 19 countries. In fiscal year 2024, MSCI reported revenues of $2.86 billion (+17% year-over-year) and adjusted EPS of $16.14, driven by the recurring subscription revenue model where institutional investment managers pay annual license fees to use MSCI's indices as performance benchmarks and the basis for ETF and structured product creation — generating subscription renewal rates above 93% annually as institutional investment workflows become structurally dependent on MSCI benchmark attribution. CEO Henry Fernandez has built MSCI into the global benchmark standard for international equity investment: the MSCI World Index and MSCI Emerging Markets Index are the most widely used benchmarks for international institutional equity allocation — when a US pension fund allocates to "international developed market equities," the performance is typically measured against the MSCI World ex-US Index, creating a permanent demand for MSCI data. The index-linked ETF asset base (BlackRock's iShares, Vanguard, and State Street use MSCI indices as ETF benchmarks — iShares MSCI Emerging Markets ETF alone holds $20+ billion in AUM paying MSCI licensing fees on every dollar managed) generates asset-linked revenue that scales automatically with ETF AUM growth.